TrialThe Lancet. Oncology2021

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Joaquim Bellmunt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.